Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose intranasal GSK256066 and fluticasone propionate in seasonal allergic rhinitis (Vienna Challenge Chamber)
2007-005301-22Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in seasonal allergic rhinitis (SAR) comparing Fluticasone propionate, GSK256066 and GSK256066 + fluticasone propionate (3 arms). Primary endpoint: Weighted mean Total Nasal Symptom Score (TNSS) 1–4 hours post-dose on Day 2. Started Jan 2008; status: completed.
02
Drugs
GSK256066fluticasone propionate
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2007-005301-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005301-22.